Drug intelligence / Profile preview

CRN04777

Development stage: Discontinued
Lead developer: Crinetics Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

CRN04777 is an orally administered nonpeptide selective **somatostatin receptor type 5 (SST5) agonist**. It is being developed as a treatment for **congenital hyperinsulinism (HI)**, a rare genetic disorder that causes life-threatening hypoglycemia due to excessive insulin secretion. CRN04777 works by inhibiting insulin secretion, which helps to normalize blood glucose levels.

Targets

SSTR5 (Somatostatin receptor 5)

Beyond the preview

Go deeper on CRN04777.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CRN04777.

Explore the full profile